

Patent No. 295334US0PCT



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAIL STOP PCT

IN RE APPLICATION OF: Haruyasu YAMAGUCHI, et al.

SERIAL NO: 10/589,969

GAU:

FILED: August 18, 2006

EXAMINER:

FOR: MONOCLONAL ANTIBODY AND USE THEREOF

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon
Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Surinder Sachar
Registration No. 34,423



Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 295334US0PCT	SERIAL NO. 10/589,969		
				APPLICANT Haruyasu YAMAGUCHI, et al.			
LIST OF REFERENCES CITED BY APPLICANT		FILING DATE August 18, 2006		GROUP			
		U.S. PATENT DOCUMENTS					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
	AE	94 17197	08-04-94	WO (with English abstract)	YES	NO	NO
	AF	0 125 023	11-14-84	EP			NO
	AG	0 239 400	09-30-87	EP			NO
	AH	90 07861	07-26-90	WO			NO
	AI	94 20632	09-15-94	WO (with English abstract)			NO
	AJ						
	AK						
	AL						
	AM						
	AN						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AO	MATHEWS, Paul M. et al., "Calpain Activity Regulates the Cell Surface Distribution of Amyloid Precursor Protein", The Journal of Biological Chemistry, Vol. 277, No. 39, pgs. 36415-36424, 2002.					
	AP	VANDERMEEREN, Marc et al., "The Functional γ -Secretase Inhibitor Prevents Production of Amyloid β 1-34 in Human and Murine Cell Lines", Neuroscience Letters, Vol. 315, No. 3, pgs. 145-148, 2001.					
	AQ	MATHEWS, Paul M. et al., "Alzheimer's Disease-Related Overexpression of the Cation-Dependent Mannose 6-Phosphate Receptor Increases A β Secretion", The Journal of Biological Chemistry, Vol. 277, No. 7, pgs. 5299-5307, 2002.					
	AR	JANUS, Christopher et al., "A β Peptide Immunization Reduces Behavioural Impairment and Plaques in a Model of Alzheimer's Disease", Letters to Nature, Vol. 408, No. 6815, pgs. 978-983, 2000.					
	AS	TAMAOKA, Akira, "Alzhermer-Byo no Kotai Ryoho", Gendai Iryo, Vol. 34, No.1, pgs. 237-244, 2002.					
	AT	KINEBUCHI, Miyuki et al., "A Novel Cell Surface Antigen Involved in Thymocyte and Thymic Epithelial Cell Adhesion", The Journal of Immunology, Vol. 146, NO. 11, pgs. 3721-3728, 1991.					
	AU	MORISHIMA-KAWASHIMA, Maho et al., "Effect of Apolipoprotein E Allele ϵ 4 on the Initial Phase of Amyloid β -Protein Accumulation in the Human Brain", American Journal of Pathology, Vol. 157, No. 6, pgs. 2093-2099, 2000.					
	AV	ERLANGER, Bernard F. et al., "Steroid-Protein Conjugates", Departments of Microbiology, Biochemistry, and Obstetrics, and Gynecology, Collage of Physicians, Columbia University, Vol.234, No. 5, pgs. 1090-1094, 1958.					
	AW	KARU, Alexander E. et al., "Synthesis of Haptens and Derivation of Monoclonal Antibodies for Immunoassay of the Phenylurea Herbicide Diuron", J. Agric. Food Chem., Vol. 42, NO. 2, pgs. 301-309, 1994.					
	AX	YAZAKI, Paul J. et al., "Humanization of the Anti-CEA T84.66 Antibody Based on Crystal Structure Data", Protein Engineering, Design & Selection, Vol.17, No. 5, pgs. 481-489, 2004.					
	AY	CARTER, Paul et al., "Humanization of an Anti-p 185 ^{HER2} Antibody for Human Cancer Therapy", Proc. Natl. Acad. Sci., Vol. 89, pgs. 4285-4289, 1992.					
	AZ	KOBAYASHI, Tobinai K. et al., "Feasibility and Pharmacokinetic Study of a Chimeric Anti-CD-20 Monoclonal Antibody (IDE-C2B8, Rituximab) in Relapsed B-Cell Lymphoma. The IDE-C2B8 Study Group.", Ann. Oncol., Vol. 9, No. 5, pgs. 1-2, 1998.			<input type="checkbox"/> Additional References sheet(s) attached		
Examiner				Date Considered			

U.S. PCT Application Serial No: 10/589,969

Filed: August 18, 2006

Haruyasu YAMAGUCHI, et al.

Docket No. 295334US 0PCT

STATEMENT OF RELEVANCY

- 1) References AO - AS have been cited in the International Search Report. A copy of these references is being submitted herewith.
- 2) References [REDACTED] have been cited in the corresponding [REDACTED] Search Report. A copy of these references is being submitted herewith.
- 3) References AT - AZ and AE - AI are discussed in the specification. A copy of these references is being submitted herewith.
- 4) References [REDACTED] are additional prior art known to Applicant. A copy of these references is being submitted herewith.